title: Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials.
abstract: OBJECTIVE
  Examine the benefits/risks of beta-blockers for pregnancy hypertension.
  
  
  METHODS
  Meta-analysis of relevant trials identified by comprehensive literature review (1966-97).
  
  
  RESULTS
  Included were 30 trials for pregnancy hypertension, and four others for perinatal outcomes only. For mild chronic hypertension treated throughout pregnancy (n=2 trials), oral beta-blockers (compared with no therapy) were associated with an inconsistent increase in small for gestational age (SGA) infants (OR 2.46 [1.02, 5.92]). For mild-moderate 'late-onset' pregnancy hypertension (i.e. either chronic treated only late in pregnancy, or pregnancy-induced) (n=8 trials), oral beta-blockers (compared with no therapy) were associated with a decrease in severe hypertension (OR 0.27 [0.16, 0.451), borderline decrease in development of proteinuria (OR 0.69 [0.48, 1.02]), decrease in RDS (OR 0.33 [0.13, 0.85]), but a borderline increase in SGA infants (OR 1.47 [0.96, 2.26]). Beta-blockers were equivalent to other agents (n=15 trials). For severe 'late-onset' pregnancy hypertension (n=5 trials), i.v. labetalol produced less maternal hypotension (OR 0.13 [0.03, 0.71]) and fewer cesareans (OR 0.23 [0.13, 0.63]) than i.v. hydralazine/diazoxide.
  
  
  CONCLUSIONS
  It is not clear that the benefits outweigh the risks when beta-blockers are used to treat mild to moderate chronic or pregnancy-induced hypertension, given the unknown overall effect on perinatal outcomes. For severe 'late-onset' pregnancy hypertension, i.v. labetalol is safer than i.v. hydralazine or diazoxide.
authors.affiliation: Division of Clinical Pharmacology/Toxicology, The Hospital for Sick Children, Toronto, Ont., Canada. laura.magee@utoronto.ca
authors.forename: L A
authors.initials: LA
authors.lastname: Magee
authors.forename: E
authors.initials: E
authors.lastname: Elran
authors.forename: S B
authors.initials: SB
authors.lastname: Bull
authors.forename: A
authors.initials: A
authors.lastname: Logan
authors.forename: G
authors.initials: G
authors.lastname: Koren
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D000319:Adrenergic beta-Antagonists